Jonathan Aronbayev, MD
Internal Medicine · Briarwood, NYNPI 1750318721
Payments from drug & device makers
Across 125 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$793
- Aimmune Therapeutics, Inc.$305
- Novo Nordisk$289
- Amgen$177
- Astellas Pharma US Inc$158
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$157
- plus $810 from 16 others
What the payments were for
- Food & beverage$2,685100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $793 |
| Aimmune Therapeutics, Inc. | 13 | $305 |
| Novo Nordisk | 14 | $289 |
| Amgen(2 entities) | 9 | $177 |
| Astellas Pharma US Inc | 7 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $157 |
| Johnson & Johnson | 7 | $119 |
| Scilex Pharmaceuticals Inc. | 5 | $102 |
| Novartis | 4 | $81 |
| Pfizer | 4 | $80 |
| Paratek Pharmaceuticals, Inc. | 3 | $68 |
| Ardelyx, Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Ironwood Pharmaceuticals, Inc | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Gilead | 1 | $31 |
| Exact Sciences | 1 | $31 |
| Abbott | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| AstraZeneca | 1 | $25 |
| GSK | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $20 |
How this compares
$2,690 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 261 | $152,694 |
| LinzessLinaclotide | 290 | $148,987 |
| ZenpepLipase/Protease/Amylase | 123 | $146,945 |
| FarxigaDapagliflozin Propanediol | 216 | $135,920 |
| JanuviaSitagliptin Phosphate | 238 | $131,742 |
| EliquisApixaban | 194 | $128,945 |
| JanumetSitagliptin Phos/Metformin Hcl | 184 | $118,583 |
| OzempicSemaglutide | 109 | $104,524 |
| Nurtec OdtRimegepant Sulfate | 71 | $79,948 |
| JardianceEmpagliflozin | 108 | $71,554 |
| CreonLipase/Protease/Amylase | 59 | $47,258 |
| VemlidyTenofovir Alafenamide | 32 | $43,972 |
| TrulicityDulaglutide | 41 | $38,596 |
| MounjaroTirzepatide | 34 | $38,439 |
| LatudaLurasidone Hcl | 26 | $34,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $80 | $208,893265 claims |
| AbbVieLinzess, Creon, Restasis | $793 | $204,145366 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $25 | $163,194283 claims |
| Aimmune Therapeutics, Inc.Zenpep | $305 | $146,945123 claims |
| Novo NordiskOzempic | $289 | $104,524109 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $26 | $77,03575 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $24 | $46,311104 claims |
| GileadVemlidy | $31 | $43,97232 claims |
| Johnson & JohnsonInvokana, Xarelto | $119 | $37,83155 claims |
| Astellas Pharma US IncMyrbetriq | $158 | $26,67361 claims |
| AmgenProlia | $177 | $24,47215 claims |
| NovartisEntresto | $81 | $9,16114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Briarwood
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.